• HOME
  • ABOUT US
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis Launches ProteaseTag® Active Plasmin Immunoassay following CE Mark registration
Share
ProteaseTag®

ProAxsis Launches ProteaseTag® Active Plasmin Immunoassay following CE Mark registration

January 8, 2018
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology will enable academic and pharmaceutical researchers to specifically measure only the active form of plasmin, a protease associated with fibrinolysis. It is believed that plasmin is involved in the pathogenesis of lung disorders such as idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS). Plasmin activity is also dysregulated in several other disease states, including pre-eclampsia, nephrotic syndrome and diabetes mellitus. The registration of a CE Mark indicates that the ProteaseTag® Active Plasmin Immunoassay complies with EU legislation, and the company will immediately commercialise the Immunoassay through its existing network of respiratory contacts across Europe.

Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said: “This is the third product for which ProAxsis has been able to register a CE Mark, and we’re delighted to add the ProteaseTag® Active Plasmin Immunoassay to our existing portfolio of products. We’re very grateful for the support we’ve received from Invest Northern Ireland for this project. As well as being a useful research tool, Plasmin continues to interest pharmaceutical companies as a potential therapeutic target in a range of different diseases. We expect to present data on this new assay at a major respiratory conference in the second half of the year, and look forward to expanding our range of products to enable the measurement of the active form of additional proteases during 2018.”

Any queries concerning ProAxsis’ Immunoassay for measuring active plasmin, or any requests for support with measuring other active protease biomarkers using the Company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

January 8, 2018

Related News

Other posts that you should not miss.
News, ProteaseTag®

ProAxsis provides update on commercialisation progress

November 21, 2017
-
Posted by Webmaster

Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in …

Read More
November 21, 2017
Posted by Webmaster
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay

September 30, 2016
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel …

Read More
September 30, 2016
Posted by Webmaster
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis

December 23, 2016
-
Posted by Webmaster

In a significant new study, a team at the University of Dundee has shown for the first time that sputum …

Read More
December 23, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis reports first NEATstik® sale
NEXT POST →
ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis supports next generation of scientists
    October 25, 2019

    ProAxsis was delighted to support the recent School of Pharmacy Undergraduate Awards at Queen’s …

  • ProAxsis welcomes Professor Stephen Smith as new Chairman
    October 25, 2019

    ProAxsis is pleased to confirm that Professor Stephen Smith has become the Chairman …

  • New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases
    June 3, 2019

    Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • November 18, 2019
    ProAxsis shortlisted for Small Business of the Year Award
  • October 25, 2019
    ProAxsis supports next generation of scientists
  • October 25, 2019
    ProAxsis welcomes Professor Stephen Smith as new Chairman
LATEST TWEETS
Twitter
ProAxsis
Follow Me
@TimFerguson01 https://t.co/00k2mJHY4o
8 days ago
- ProAxsis
Having a great night and delighted to be shortlisted at the #AIBBEawards @eye_business
8 days ago
- ProAxsis
RT @geinarsson: Recommended preprint by Alison Dicker et al. from @ProfJDChalmers group in Dundee on "The Sputum Microbiome Is Associated w…
24 days ago
- ProAxsis
RT @ProfJDChalmers: In summary- lower microbiome diversity means more exacerbations, more lung inflammation and a higher risk of mortality…
25 days ago
- ProAxsis
Copyright © 2016-2018 - ProAxsis - All rights reserved. 
ProAxsis Launches ProteaseTag® Active Plasmin Immunoassay following CE Mark registration | ProAxsis